Aspira Pathlab & Diagnostics Ltd
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
- Market Cap ₹ 60.2 Cr.
- Current Price ₹ 58.5
- High / Low ₹ 107 / 25.0
- Stock P/E 29.8
- Book Value ₹ 11.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.95 times its book value
- Promoter holding is low: 18.4%
- Promoter holding has decreased over last 3 years: -17.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 13.20 | 22.00 | |
| 14.75 | 18.87 | |
| Operating Profit | -1.55 | 3.13 |
| OPM % | -11.74% | 14.23% |
| 0.42 | 0.39 | |
| Interest | 0.00 | 0.00 |
| Depreciation | 1.54 | 1.49 |
| Profit before tax | -2.67 | 2.03 |
| Tax % | 0.00% | 0.00% |
| -2.67 | 2.02 | |
| EPS in Rs | -2.59 | 1.96 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 176% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 3% |
| 1 Year: | 89% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 10.29 | |
| Reserves | 1.87 | |
| 3.20 | ||
| 2.10 | ||
| Total Liabilities | 17.46 | |
| 6.53 | ||
| CWIP | 0.00 | |
| Investments | 0.08 | |
| 10.85 | ||
| Total Assets | 17.46 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1.83 | ||
| 0.12 | ||
| -0.99 | ||
| Net Cash Flow | 0.95 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 38.99 | |
| Inventory Days | 50.31 | |
| Days Payable | 73.00 | |
| Cash Conversion Cycle | 16.30 | |
| Working Capital Days | 27.87 | |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 May - Newspaper Advertisement for the Standalone & Consolidated Financial Results as on March 31, 2025
-
100% Acquisition Of Stake And Strike Off Of Aspira DNA Diagnostics Gujarat LLP
16 May - Aspira to acquire 100% stake in associate Aspira DNA Diagnostics Gujarat LLP and strike it off.
-
Re-Appointment Of Dr. Pankaj Shah (DIN: 02836324) As Managing Director & CEO Subject To The Members Approval For A Period Of Three (3) Years
16 May - Re-appointment of Dr. Pankaj Shah as MD & CEO from Aug 2025 to Jul 2028.
-
Intimation Of Appointment Of Secretarial Auditor And Internal Auditor
16 May - Appointed Secretarial Auditor for 5 years and Internal Auditor for FY 2025-26.
-
Integrated Filing (Financial)
16 May - Audited FY25 results approved; MD re-appointed; secretarial and internal auditors appointed; postal ballot planned.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is in the business of running, owning, managing and administering Diagnostics Centers in Mumbai